What's Happening?
AstraZeneca and Daiichi Sankyo's DATROWAY (datopotamab deruxtecan-dlnk) has demonstrated a significant improvement in overall survival for patients with metastatic triple-negative breast cancer (TNBC)
in the TROPION-Breast02 Phase III trial. The drug showed a 5-month improvement in median overall survival compared to chemotherapy and reduced the risk of disease progression or death by 43%. These results were presented at the 2025 European Society for Medical Oncology Congress. DATROWAY is the first therapy to significantly improve survival in this patient population, offering an alternative to chemotherapy.
Why It's Important?
The results from the TROPION-Breast02 trial represent a major advancement in the treatment of metastatic TNBC, a cancer subtype with poor prognosis and limited treatment options. The significant improvement in survival and disease progression offers hope for patients who are not candidates for immunotherapy. This development could shift the standard of care for TNBC, providing a new first-line treatment option that prolongs life and delays disease progression.
What's Next?
AstraZeneca and Daiichi Sankyo are conducting additional Phase III trials to evaluate DATROWAY in combination with other treatments and in different stages of TNBC. The ongoing research aims to expand the use of DATROWAY and explore its potential in early-stage, potentially curative settings. The companies will continue to present updated trial results and seek regulatory approvals to make DATROWAY widely available to patients.
